Moderna Inc. (MRNA) and Mitsubishi Tanabe Pharma Corporation have partnered to jointly promote Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax.
As per the agreement, Moderna will handle the manufacturing, sales, medical education and distribution of its mRNA respiratory vaccines. The companies will engage in activities to enable broad access to Moderna's mRNA respiratory portfolio to have the maximum impact on public health in Japan.
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.